Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the effectiveness and safety of rTMS treatment under the guidance of personalized Brain Functional Sectors (pBFS) for the cognitive ability of patients with mild Alzheimer's disease.


Clinical Trial Description

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by memory impairment and cognitive decline. Personalized brain functional sectors (pBFS) using resting-state functional MRI scans have shown promise in precisely identifying individualized brain function networks. In this study, we aim to select tailored stimulation sites within the working memory network (WMN) or the default mode network (DMN) as intervention targets for mild AD patients using pBFS. To evaluate the effectiveness and safety of this intervention, participants will be randomized into four groups: active repetitive transcranial magnetic stimulation (rTMS) to the WMN group, active rTMS to the DMN group, and sham rTMS to either the WMN or DMN group at a ratio of 2:2:1:1. Each participant will receive 3600 pulse active or sham rTMS in each session, consisting of two 1800 pulse treatments with a 50-minute break in between. Two separate treatment sessions will be administered daily, resulting in a sum of 7200 pulses per day. The intervention will be administered for 15 continuous days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05872243
Study type Interventional
Source Changping Laboratory
Contact Na Xu, Ph.D.
Phone +8618810069676
Email naxu@cpl.ac.cn
Status Recruiting
Phase N/A
Start date September 11, 2023
Completion date August 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT00243451 - Early Detection of Mild Cognitive Impairment in Individual Patients N/A
Recruiting NCT05417555 - Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease N/A
Terminated NCT01482013 - Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease Phase 1
Completed NCT03186989 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT03752294 - A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age. Phase 1
Completed NCT01013610 - An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease Phase 1
Recruiting NCT06058234 - Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Active, not recruiting NCT03234686 - Deferiprone to Delay Dementia (The 3D Study) Phase 2
Completed NCT05233774 - Lomecel-B Effects on Alzheimer's Disease Phase 2
Withdrawn NCT05032482 - WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease N/A
Terminated NCT00582855 - Effect of AQW051 in Patients With Memory Impairment Phase 2
Completed NCT01061489 - Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment N/A
Completed NCT01548287 - A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment Phase 2
Terminated NCT00706186 - Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients Phase 4